An Investigational Study of Gardasil™ (qHPV Vaccine) in Reducing the Incidence of Anogenital Warts in Young Men (V501-020)

NCT00090285 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

4065

Enrollment

INDUSTRY

Sponsor class

Conditions

Condylomata Acuminata

Interventions

BIOLOGICAL: (Gardasil™) human papillomavirus (types 6, 11, 16, 18) recombinant vaccine
BIOLOGICAL: Comparator: placebo (unspecified)

Sponsor

Merck Sharp & Dohme LLC